Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 24, 2023 - Issue 2
Submit an article Journal homepage
1,855
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Relationship between the dose titration and adherence of mirogabalin in patients with peripheral neuropathic pain depending on renal function: a nationwide electronic medical record database study

Karin Katoa Department of Patient Safety Unit/Anesthesia, Kyoto University Hospital, Kyoto, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9181-2500View further author information
ORCID Icon,
Sho Kodamab Medical Affairs Division, Daiichi Sankyo Co., Ltd, Tokyo, JapanView further author information
,
Kazuhito Shiosakaic Digital Transformation Management Division, Daiichi Sankyo Co., Ltd, Tokyo, JapanView further author information
&
Takeshi Kimurad Research and Analytics Department, Real World Data Co., Ltd., Kyoto, JapanORCID Iconhttps://orcid.org/0000-0001-5254-3507View further author information
ORCID Icon
Pages 267-282 | Received 25 Oct 2022, Accepted 01 Dec 2022, Published online: 15 Dec 2022

References

  • Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204–2205.
  • Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021;101:259–301.
  • Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J Pain Symptom Manage. 2017;53:614–629.
  • Ushida T, Matsui D, Inoue T, et al. Recent prescription status of oral analgesics in Japan in real-world clinical settings: retrospective study using a large-scale prescription database. Expert Opin Pharmacother. 2019;20:2041–2052.
  • Taylor RS. Epidemiology of refractory neuropathic pain. Pain Pract. 2006;6:22–26.
  • Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17:1010–1018.
  • The committee for the guidelines for the pharmacologic management of neuropathic pain of JSPC. Guidelines for the pharmacologic management of neuropathic pain second edition. cited 2022 Sep 22]. Available from 2022 Sep 22: https://minds.jcqhc.or.jp/docs/minds/Pharmacologic-management-of-neuropathic-pain/Pharmacologic-management-of-neuropathic-pain.pdf#view=FitV.
  • Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160:1175–1185.
  • Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299–1306.
  • Kato J, Matsui N, Kakehi Y, et al. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia. Medicine (Baltimore). 2020;99:e21976.
  • Baba M, Matsui N, Kuroha M, et al. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020;11:693–698.
  • Kato J, Inoue T, Yokoyama M, et al. A review of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, for the treatment of peripheral neuropathic pain. Expert Opin Pharmacother. 2021;22:2311–2322.
  • Daiichi Sankyo Co., Ltd. Tarlige® (mirogabalin) Tablets, 2.5 mg, 5 mg, 10 mg, 15 mg, package insert. Japanese. [cited 2022 Sep 22]. Available from 2022 Sep 22: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/430574_1190026F1028_1_07
  • Baba M, Takatsuna H, Matsui N, et al. Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia: a phase III, open-label, 14-week study. J Pain Res. 2020;13:1811–1821.
  • Johnson P, Becker L, Halpern R, et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013;33:35–44.
  • Hoffman EM, Staff NP, Robb JM, et al. Impairments and comorbidities of polyneuropathy revealed by population-based analyses. Neurology. 2015;84:1644–1651.
  • Callaghan BC, Reynolds E, Banerjee M, et al. Longitudinal pattern of pain medication utilization in peripheral neuropathy patients. Pain. 2019;160:592–599.
  • Christensen DH, Knudsen ST, Nicolaisen SK, et al. Can diabetic polyneuropathy and foot ulcers in patients with type 2 diabetes be accurately identified based on ICD-10 hospital diagnoses and drug prescriptions? Clin Epidemiol. 2019;11:311–321.
  • Gudin J, Fudin J, Wang E, et al. Treatment patterns and medication use in patients with postherpetic neuralgia. J Manag Care Spec Pharm. 2019;25:1387–1396.
  • Udall M, Harnett J, Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J Med Econ. 2012;15:361–370.
  • Yeh YC, Cappelleri JC, Marston XL, et al. Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: a MarketScan database study. PLoS One. 2021;16:e0242467.
  • Ushida T, Yokoyama M, Shiosakai K, et al. A large-scale database study for the prescription status of a new voltage-gated Ca 2+ channel α 2 δ ligand, mirogabalin, in Japan. Expert Opin Pharmacother. 2022;23:273–283.
  • Kimura Y, Yamaguchi S, Suzuki T, et al. Switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain: a Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study). Pain Ther. 2021;10:711–727.
  • Nikaido T, Takatsuna H, Tabata S, et al. Efficacy and safety of add-on mirogabalin to NSAIDs in lumbar spinal stenosis with peripheral neuropathic pain: a randomized, open-label study. Pain Ther. 2022;20:1–20.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.